Predictors of symptomatic remission in patients with first-episode schizophrenia: A 16 years follow-up study by Marchesi, Carlo et al.
Available online at www.sciencedirect.com
ScienceDirect
Comprehensive Psychiatry 55 (2014) 778–784
www.elsevier.com/locate/comppsychPredictors of symptomatic remission in patients with first-episode
schizophrenia: A 16 years follow-up study
Carlo Marchesia,b,⁎, Andrea Affaticatib, Alberto Monicib, Chiara De Panfilisa,b,
Paolo Ossolaa, Matteo Tonnab
aDepartment of Neuroscience, Unit of Psychiatry, University of Parma, Italy
bMental Health Department, Local Health Agency, Parma, ItalyAbstract
Objective: Recent views on schizophrenia outcome and treatment suggest that symptomatic remission is possible, and a definition of
remission has been proposed by the Remission in Schizophrenia Working Group (RSWG).
This study evaluated whether patients who achieved remission after several years of illness (R) showed psychopathological differences at
the onset of their disorder compared to non-remitted (NR) patients.
Method: Forty-eight patients with first-episode schizophrenia were evaluated with the Positive and Negative Symptoms Scale (PANSS) both
at the onset of illness and after a mean period of 16 years. Patients were defined as R or NR according to the RSWG criteria.
Results: Eighteen patients (37.5%) were classified as R at follow-up. At onset, R patients showed a lower illness severity, less severe
negative and general psychopathology symptoms compared to NR. Furthermore, they underwent fewer psychotic episodes than NR over the
course of follow-up. Remission was predicted by lower severity of negative and general psychopathology symptoms at onset and by lesser
number of psychotic episodes during follow-up.
Conclusions: The symptomatic remission may be a viable outcome in schizophrenia, particularly for patients with a mild illness and less
severe negative symptoms at onset and with few psychotic episodes over time.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Since the description of “dementia praecox” by
Kraepelin [1], schizophrenia has been conceptualized as
a chronic illness leading to mental deterioration, lack of
volition and social incompetence with no hope for
sustained remission or recovery [2]. Initially, diagnosis
and prognosis were essentially the same [3] and any
dramatic improvement or recovery during the course of the
illness was viewed as signs of earlier misdiagnosis [4].
More recently, long-term follow-up studies have shown
that the course of schizophrenia is highly heterogeneous
[5,6]; outcome in schizophrenia is a complex and multi-
determinate phenomenon and the ability of this diagnosis⁎ Corresponding author at: Università di Parma, Dipartimento di
Neuroscienze, Unità di Psichiatria, Ospedale-Padiglione Braga, Via Gramsci
14, 43125 Parma, Italy. Tel.: +39 0521 903594; fax: +39 0521 347047.
E-mail address: carlo.marchesi@unipr.it (C. Marchesi).
0010-440X/$ – see front matter © 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.comppsych.2013.12.011to specifically predict a poor outcome has often been
overstated [7]. For decades, the lack of generally accepted
definition of treatment response, remission or recovery,
which were considered largely impossible, represented a
major problem for schizophrenia research [8]. Thus, the
comparability of the research findings was limited by the
variability of the criteria used in different studies [9]. In
clinical practice the so-called “rule of thirds” became
popular: in a group of schizophrenic patients one-third
improves, one third deteriorates and one third has an
intermediate course. But “the rule of thirds” did not have
an empirical basis [10]. In order to improve the
understanding of schizophrenia and its treatment options,
the Remission in Schizophrenia Working Group (RSWG)
[11] posited that “symptomatic remission is a definable
concept and an achievable stage in the treatment of
schizophrenia”, since “psychosocial therapies and rehabil-
itation are most effective when positive and negative
symptoms are adequately controlled”. The RSWG pro-
posed specific criteria for symptomatic remission with the
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range of available therapeutic options and to support a
positive, longer-term approach regarding outcome for
patients with schizophrenia. Standardized RSWG consen-
sus criteria for remission are based on severity of core
psychopathological symptoms as assessed by the PANSS
(symptomatic remission) which is sustained over a
minimum of 6 months (time criterion) [11]. According to
these criteria, a percentage of patients ranging from 45% to
70% were defined as remitters at some point during the
course of their illness [12]. Concerning the identification of
early predictors of symptomatic remission, a shorter
duration of untreated psychosis (DUP), a better premorbid
adjustment, lower illness severity at baseline, early
symptomatic improvement, medication adherence and
remitted substance abuse are thought to increase the
likelihood for remission [12]. However, some of the
existing studies failed to fully apply the RSWG criteria, for
example by omitting the time criterion or by using
different measures of symptom severity [12]. In addition,
most of the available studies assessed the remission rate
over a short time period, while only few studies employed
a follow-up longer than 2 years. Thus, as claimed by
Lambert [12], “comparability in terms of validity of
criteria as well as frequencies and predictors of remission
is limited”, and further research is warranted in this area.
Patients achieving RSWG remission criteria are likely to
be highly heterogeneous in terms of their psychopatholog-
ical features. Specifically, they could show at the onset
peculiar patterns and varying severity of the negative,
disorganized and psychoticism (or reality distortion) di-
mensions, which represent related but distinguishable
components of the schizophrenia process [11,13,14].
Previous studies reported that more severe negative
symptoms at baseline robustly predict poor outcome
[2,15–18]. However, the role of any specific psychopath-
ological pattern in predicting long-term remission is still far
to be established: while one study [19] confirmed that
higher PANSS negative symptom scores at baseline
predicted a lower likelihood of remission at 6-year
follow-up, another study [20] did not report any psycho-
pathological differences at the early stage of illness between
remitted and non-remitted patients at a 7-year follow-up.
Such conflicting findings may be partly due to the different
phases of illness in which patients were evaluated, i.e., first-
episode [20] versus chronic schizophrenia [19]. Assessing
symptom severity at different time points during the course
of the illness may be critical for the evaluation of the course
and stability of psychopathological dimensions.
Therefore, the present study aimed to investigate whether
the severity of positive, disorganized and negative symptoms
assessed at onset in first-episode patients with schizophrenia
predicted remission (RSWG criteria) after several years (16
on average) of illness. In addition, a secondary aim was to
evaluate how these three psychopathological dimensions
changed over time.2. Materials and method
2.1. Sample
The study participants were recruited from patients who
were consecutively admitted to the Psychiatric Clinic of the
University of Parma, from January 1995 to December 1999
for a first psychotic episode. This study is a part of a more
extensive evaluation of long-term outcome in patients
with a first psychotic episode approved by the Local
Ethic Committee.
Patients were included in the study if: 1) they were aged
over 17 years; 2) they were hospitalized for the first time in a
psychiatric unit for a first psychotic episode; 3) they were
discharged with a diagnosis of schizophrenia, according to
the DSM-IV; 4) they gave a written informed consent.
Patients were excluded from the study if: 1) they were
affected by drug abuse or drug dependence, delirium, mental
retardation or organic mental disorders; 2) they had been
previously treated with psychotropic medication; 3) they did
not assure treatment adherence or they discontinued the
treatment program for more than two consecutive visits (see
follow-up evaluation).2.2. Assessment
The period of enrolment lasted from January 1995 to
December 1999. Patients were evaluated at two points in
time, i.e., during the index hospital admission and then
in 2010.2.2.1. Baseline assessment
The baseline evaluation was carried out within the first
week of the index hospitalization. Socio-demographic
variables recorded at baseline were: age, gender, years of
education, marital and employment status, housing situation,
age at onset of schizophrenia and the time passed from the
onset of first psychotic symptoms or behavioural changes to
the hospitalization where patients received treatment for the
first time (see exclusion criteria).
To formulate the diagnosis, we used the information
obtained from the Structured Clinical Interview for DSM-IV,
carried out by trained psychiatrists, together with the
information collected from family members, medical records
and primary treating physicians.
The severity of symptoms was measured with the Positive
and Negative Symptoms Scale (PANSS) [21]. According to
the PANSS criteria, patients were defined as affected by
positive schizophrenia (if they reported a score equal or
higher than four in at least three items of positive scale and in
less than three items of negative scale), negative schizo-
phrenia (if they reported a score equal or higher than four in
at least three items of negative scale and in less than three
items of positive scale) or mixed schizophrenia (if they
reported a score equal or higher than four in at least three
items of positive and negative scales).
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After discharge from hospital, patients accessed to
continuous and reasonably comprehensive public mental
health services [22], where they attended nearlymonthly visits.
During each visit their psychopathological condition,
treatment adherence, medications prescription, use of illicit
drugs were monitored from a clinical point of view. The
number of psychotic episodes and time of hospitalization
were also computed.
Patients were re-assessed in 2010 by a psychiatrist, blind
to the baseline evaluation. The follow-up assessment
consisted in the administration of SCID-IV and PANSS.
After eight months patients were re-evaluated with the
PANSS to verify whether the time criterion of 6 months
requested for remission, as suggested by RSWG, was
satisfied. Patients were defined in remission (R) or in non-
remission (NR), according to the criteria (both severity and
time criteria) proposed by the RSWG.
2.4. Treatment
All patients were treated with antipsychotic medications.
The choice of medication was made on the base of clinicalTable 1
Socio-demographic and clinical features of schizophrenic patients with or without
Remis
Yes n = 18 No n
n % n
Gender
Male 10 55.5 19
Marital status
Never married 13 72.2 22
Married 5 21.8 4
Divorced/widowed 0 0.0 4
Working status
Never occupied 4 22.2 18
Occupied 14 77.8 12
Living status
Living alone 8 44.4 10
Living with someone 10 55.6 20
Schizophrenia type
DSM-IV
Paranoid 16 88.9 23
Disorganized 0 0.0 5
Undifferentiated 2 11.1 2
PANSS scores
Positive 15 83.3 10
Negative 0 0.0 1
Mixed 3 16.7 19
Mean ± SD Mean ± SD
Age 41.0 ± 11.3 46.5 ± 14.
Age at onset 22.2 ± 3.8 21.6 ± 5.8
DUP, weeks 18.0 ± 4.5 19.7 ± 4.4
At follow-up
Duration years 16.3 ± 5.1 16.0 ± 4.8
No. of psychotic episodes 2.2 ± 0.6 3.6 ± 1.0
Hospitalization months 5.3 ± 0.6 7.5 ± 1.9evaluation and according to the preference of patients and
their relatives.
To maximize the treatment adherence, a medication
control by relatives was recommended and the count of pills
was performed at any time the medication was prescribed. In
patients who did not assure a treatment adherence the use of
a long-acting medication was proposed.
2.5. Data analysis
Before the start-up of the study and the follow-up
evaluations an inter-rater reliability was calculated for the
diagnosis of schizophrenia (baseline: k = .92; follow-up:
k = .95) and for the PANSS total score (baseline: k = .82;
follow-up: k = .80).
The clinical and socio-demographic features were
compared in R and in NR using two-tailed Student’s t test
for continuous variables andχ2 test for categorical variables.
The change of symptom severity between baseline and
follow-up assessments was evaluated in R and in NR using
two-tailed Student’s t test for paired data.
A logistic regression analysis was next used to evaluate
which factors may influence the likelihood to achieve
remission. In this analysis, remission vs. non-remissionremission.
sion χ2 p






















Mean ± SD T p
1 43.2 ± 11.1 1.3 .17
21.8 ± 5.1 .3 .70
19.0 ± 4.5 1.21 .20
16.2 ± 4.9 .2 .85
6.3 ± 6.4 4.7 b.001
6.6 ± 1.8 4.6 b.001
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variables which showed a significant difference between R
and NR patients at baseline (see Table 1) were entered as
indipendent variables.3. Results
3.1. Sample
During the period of enrolment, 70 patients were
consecutively admitted to the Psychiatric Clinic of the
University of Parma for a first psychotic episode and
discharged with a diagnosis of schizophrenia. Among them,
56 accepted to participate in the study.
In 2010 eight patients were lost to follow-up: six patients
for the change of residence and two patients for refusing to
further undergo evaluation. Therefore 48 patients were re-
assessed at follow-up.
The SCID-IV re-administration confirmed the stability of
schizophrenia diagnosis in all 48 patients, and 18 of them
satisfied remission criteria (37.5%) (R), whereas the
remaining 30 patients (62,5%) (NR) did not reach remission.
None of them was using illicit drugs.
Among remitted patients, 3 of them (16.7%) were in
complete symptomatic recovery, 9 (50%) showed minimal
symptom severity and 6 (33.3%) had mild symptom severity
at follow-up.
3.2. Socio-demographic characteristics
Only the working status was different in R and NR
patients: R patients were more likely to be employed than
NR patients (χ2 = 6.4; p = 0.01) (Table 1). The duration of
untreated psychosis was shorter in this sample (Table 1) and
no difference was found between R and NR patients.
At follow-up, R and NR did not differ with respect to the
duration of illness, whereas the number of psychotic
episodes and time of hospitalization were higher in NR
than in R (Table 1).
3.3. Symptom severity
At baseline a lesser symptom severity was found in R than
in NR patients: all PANSS dimension scores (positive,Table 2
Symptom severity (PANSS scores), in remitted (R) and in non-remitted (NR) pati
PANSS symptoms Remission
Yes No
n = 18 n = 3
Baseline Follow-up Baseline
Positive 24.8 ± 3.7 11.0 ± 2.7 28.1 ± 4.0
Negative 17.8 ± 3.1 16.5 ± 2.6 25.3 ± 4.4
General 46.0 ± 4.1 32.5 ± 5.5 55.8 ± 5.4
Total score 88.8 ± 6.2 60.7 ± 10.5 109.2 ± 10.0
# p b .01.
⁎ p b .001.negative and general psychopathology) were lower in R than
in NR patients (Table 2). Eleven patients (22.9%) did not
have negative symptoms at the first episode.
At follow-up, symptoms severity had decreased in both
groups: such decrease was statistically significant for
PANSS positive and general psychopathology scores, but
not for the negative symptoms score, in both R and NR
patients (Table 2).
3.4. Treatment
Forty-one patients (85.5%) were treated with oral
antipsychotics and the remaining 7 patients (14.5%) received
a long-acting antipsychotic. A second-generation antipsy-
chotic was administered in 34 patients (70.8%) and a first-
generation antipsychotic was used in 14 patients (29.2%).
3.5. Likelihood of remission
The likelihood to achieve remission was predicted by the
severity of general psychopathology and negative symptoms
at onset and by the number of psychotic episodes during
follow-up, while PANSS type of schizophrenia, PANSS
positive symptoms and time of hospitalization did not exert
any effect (Table 3).4. Discussion
The current study evaluated the symptomatic course of
schizophrenia by assessing 48 patients at their first episode
and after a mean period of 16 years.
At follow-up, 18 patients (37.5%) (R) satisfied the
remission criteria (both severity and time criteria) proposed
by the RSWG [11], whereas the remaining 30 patients did
not achieve remission (NR).
Remitters and non-remitters showed significant psycho-
pathological differences since their first episode of illness. R
patients displayed milder positive and negative symptoms
and a lower overall symptom severity at baseline than NR.
These data are in keeping with previous findings of less
severe early negative symptoms in R patients [19], but
contradict the results of Ceskova et al. [20], who did not find
any difference between R and NR at their first episode ofents.
t-test for pared sample
Yes vs no Baseline vs follow-up
0 Baseline Follow-up Yes No
Follow-up t t t t
17.2 ± 5.8 2.7# 4.2⁎ 13.9⁎ 11.5⁎
24.1 ± 5.0 6.1⁎ 5.6⁎ 1.6 1.7
41.7 ± 6.9 6.6⁎ 4.7⁎ 9.2⁎ 12.9⁎
83.0 ± 14.2 7.7⁎ 5.7⁎ 10.5⁎ 12.2⁎
Table 3
Probability to reach remission at follow-up in patients with first episode of schizophrenia.
Probability of remission
b χ2 wald p OR CI 95% R2
Step 1 .46
PANSS general psychopathology score −.38 44.9 b.001 .68 .55–.84
Step 2 .56
PANSS negative score −.49 5.6 .01 .60 .40–.91
PANSS general psychopathology score −.28 5.5 .01 .75 .59–.95
Step 3 .68
No. of psychotic episodes follow-up −1.3 7.1 .008 .68 .55–.84
PANSS negative score −1.8 2.2 .13 .16 .01–1.78
PANSS general psychopathology score −.49 2.0 .14 .60 .30–1.20
In the logistic regression analysis remission vs. non remission (0 vs 1) entered as dependent variable, whereas baseline PANSS positive, negative, and general
psychopathological scores, PANSS types of schizophrenia, number of psychotic episodes and time of hospitalization during the follow-up period enterd as
independent variables.
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men in their study, our sample had a 40% proportion of
women, who are known to be characterized by a higher rate
of remission [23]. Further, the achievement of remission was
evaluated seven years after the first episode in the study by
Ceskova et al. [20], and 16 years in the present study. The
assessment of remission at different times of schizophrenia
course may have contributed to such observed differences.
While in this sample positive and general psychopathol-
ogy symptoms severity was found to improve 16 years after
the first episode of illness, no change in negative symptoms
severity occurred. These patterns of change (for positive and
general symptoms) and stability (for negative symptoms)
were observed in both R and NR, suggesting that R and NR
patients share the same pattern of change across symptoms;
thus, the clinical differences disclosed at their first episode
were maintained during follow-up. Therefore, we can
hypothesize that patients with milder symptoms severity at
onset reached remission at follow-up when such symptoms
improved, while a comparable degree of improvement did
not translate into the achievement of remission in patients
with more severe symptoms at onset of illness.
Concerning the effect of symptoms dimensions on
remission, R patients exhibited more positive than negative
symptoms at onset, since a “positive schizophrenia”, defined
according to the PANSS criteria, was more frequently
diagnosed in R (83%) than in NR (33%) (p = 0.002).
However, logistic regression analysis demonstrated that the
likelihood to develop remission is not influenced by the
severity of positive symptoms at the first episode of illness,
suggesting that positive symptoms at onset do not impact on
later symptomatic remission. Of note, however, the number
of psychotic episodes during follow-up reduced the
likelihood of remission (OR = .68; CI95% = .55–.84)
(p = 0.008), suggesting that the recurrence of positive
symptoms during the course of illness may prevent remission.
Psychotic relapses occurring after schizophrenia onset
may have a “toxic” effect on the brain because they arebelieved to induce a progressive brain loss. This structural
brain change has been associated with the severity of
psychotic symptoms and cognitive impairment as well as
with the number and duration of psychotic episodes [24–26].
The results of this study may be interpreted as supporting
those findings: a greater number of psychotic episodes could
lead to a greater brain loss, which in turn increases the
severity of psychotic symptoms thus reducing the likelihood
of remission.
Therefore, the current study suggests that positive symp-
toms show a fluctuating course and their prognostic value
varies as a function of their recurrence rather than of their
initial severity, which in fact was found to decrease over time
in this study sample, regardless of patients’ remission status.
Conversely, negative symptoms were already present at
onset in most patients (77%), remained stable throughout the
course of the illness, and exerted a negative effect on the
achievement of remission. This finding is in keeping with
recent studies indicating an association between higher
negative symptoms at baseline and poor outcome [17–19].
Thus, in this sample of patients with schizophrenia, negative
symptoms 1) had a relevant prognostic value, reducing the
likelihood of remission; 2) were enduring, i.e., stable since
the onset of schizophrenia until 16 years thereafter (looking
refractory to the available antipsychotic treatments); 3) were
primary since they neither worsened (for the addition of
possible negative symptoms secondary to antipsychotic
drugs), nor improved (for the reduction of negative
symptoms secondary to the amelioration of positive
symptoms) during a 16 year-old follow-up; 4) characterized
each stage of the illness, being already apparent at onset in
most patients and cannot be considered as a consequence of a
chronic course. Taken together, these results support the
classical view of negative symptoms as the cornerstone of
schizophrenia [27].
In the present study, general psychopathology symptoms
were negatively related to remission and their predicting
value was even more relevant than that observed for negative
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sion represents a heterogeneous dimension, including
symptoms probably secondary to other dimensions (i.e.
anxiety and agitation induced by positive symptoms), and
symptoms that are a direct expression of the disease (i.e.
avolition). This dimension could be more sensitive to illness
severity, in a way that its predictive power is expression
of the overall illness severity rather than of the effect of
specific symptoms.
In summary, negative symptoms that are present at the
onset of schizophrenia appear stable and associated with a
poor long-term outcome in terms of symptomatic remission,
while positive symptoms seem to have less prognostic value
when assessed at onset, but their recurrence during the
course of the disorder can impede long-term remission.
The present study has the following limitations.
First, symptom severity was assessed with the PANSS
only at two points in time (i.e., at onset and after a mean
period of 16 years of illness). However, it was clinically
monitored at a monthly interval throughout the follow-up
time. Thus, we can exclude that deep fluctuations of
symptom severity had occured during the course of illness;
rather, patients with mild symptoms at onset maintained the
same symptom severity throughout the course of their
illness. Nonethless, since schizophrenia is not a stable
disorder and remission, as well as recovery, is for many
patients a time limited occurrence, we cannot exclude that
possible relapses may occur even after 16 years of follow-up
in remitted patients.
Second, all patients enrolled in this study were hospital-
ized few months after the onset of illness, resulting in a short
DUP (mean 19.0 weeks). This finding is probably due to the
fact that a program of early detection and treatment of severe
mental disorders, involving the collaboration between
general practitioners and community mental health services,
was active in the study catchment area. Therefore, the lack of
effect of DUP on functional outcome in this sample can be
explained by the early treatment intervention (i.e., within
30 weeks from the onset of psychotic symptoms or
behavioural changes in all patients). In addition, the effect
of the use of illicit drugs on the outcome could not be
evaluated in the present study, since no participants had a
diagnosis of substance use disorder during the follow-
up period.
Third, even though the treatment was clinically monitored
at each visit and strategies to prevent non-adherence were
planned during the follow-up period, we cannot rule out that
some patients were non-adherent to medications during the
time between the visits, leading to incomplete control
of symptoms.
Fourth, the current study includes patients who were
strictly treatment adherent and substance use free. Thus, the
results of the study are not applicable to overall schizophre-
nia patients.
Fifth, the study design did not provide a collection of
prognostic indices at baseline through specific scales basedupon clinical characteristics such as those developed by
Vaillant [28] and Stephens [29].
In conclusion, this study suggests that symptomatic
remission is a viable therapeutic outcome in schizophrenia,
particularly in patients presenting with a less global severity
and less severe negative symptoms at their first episode and
who display few psychotic episodes over the course of
their illness.References
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